Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1694-1700

  Leder, Benjamin Z ^a   Tsai, Joy N ^a   Uihlein, Alexander V ^a   Burnett Bowie, Sherri Ann M ^a   Zhu, Yuli ^a   Foley, Katelyn ^a   Lee, Hang ^a   Neer, Robert M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCALCIN; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROCOLLAGEN; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84899961372     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4440     Document Type: Article

References (25)

1. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1:45-52.
2. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11:325-338.
3. Dempster DW, Zhou H, Recker RR, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012; 97:2799-2808.
4. Compston J. The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine. 2012;41:11-18.
5. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
6. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503-511.
7. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, NeerRM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-1226.
8. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838-1845.
9. Deal C, OmizoM,Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20:1905-1911.
10. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet. 2013;382:50-56.
11. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
12. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12:519-528.
13. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.NEngl J Med. 2007; 356:1809-1822.
14. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
15. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443.
16. McClung MR Geusens P Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med. 2001 344 333-340.
17. Chesnut CH III, Skag A, Christ iansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
18. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
19. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001;142:4295-4304.
20. Samadfam R, Xia Q, Goltzman D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res. 2007;22:55-63.
21. Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, ResHsieh C.H. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bon e Miner Res. 2013;28:196-205.
22. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mi neral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-3076.
23. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:5 50-555.
24. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner R es. 2006;21:1785-1790.
25. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractur es. J Bone Miner Res. 2012;27:687-693.